Litigation Details for Almirall LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)
✉ Email this page to a colleague
Almirall LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)
Docket | ⤷ Sign Up | Date Filed | 2017-06-01 |
Court | District Court, D. Delaware | Date Terminated | 2019-03-11 |
Cause | 35:271 Patent Infringement | Assigned To | Joseph F. Bataillon |
Jury Demand | None | Referred To | Sherry R. Fallon |
Parties | TARO PHARMACEUTICAL INDUSTRIES LTD. | ||
Patents | 8,778,365; 9,517,219 | ||
Attorneys | Elizabeth B. Hagan | ||
Firms | Morris, Nichols, Arsht & Tunnell | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Almirall LLC v. Taro Pharmaceutical Industries Ltd.
Details for Almirall LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2018-10-23 | 113 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,517,219 B2 . (Blumenfeld, Jack…2017 11 March 2019 1:17-cv-00663 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
2019-01-23 | 137 | would induce infringement of U.S. Patent No. 9,517,219 (“the ’219 patent”) under the doctrine of equivalents…asserted claims are invalid. The ’219 patent is a method patent. The matter is set for trial on February…since the language of the asserted patent claims, and not the patent holder’s commercial product, to define… that during the prosecution of the ’219 patent, the patent examiner defined a POSA as having a level… a POSA for the ’219 patent. Taro proposes: A POSA for the ’219 patent would have had at least | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |